216 related articles for article (PubMed ID: 18948574)
21. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
Busse WW; Israel E; Nelson HS; Baker JW; Charous BL; Young DY; Vexler V; Shames RS;
Am J Respir Crit Care Med; 2008 Nov; 178(10):1002-8. PubMed ID: 18787222
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
23. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
24. Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/beta2-microglobulin(null) mice.
Kawano N; Ishikawa F; Shimoda K; Yasukawa M; Nagafuji K; Miyamoto T; Baba E; Tanaka T; Yamasaki S; Gondo H; Otsuka T; Ohshima K; Shultz LD; Akashi K; Harada M
Leukemia; 2005 Aug; 19(8):1384-90. PubMed ID: 15959532
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
26. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab.
Egan CA; Brown M; White JD; Yancey KB
Clin Immunol; 2001 Nov; 101(2):146-51. PubMed ID: 11683573
[TBL] [Abstract][Full Text] [Related]
27. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
ter Meulen CG; Göertz JH; Klasen IS; Verweij CM; Hilbrands LB; Wetzels JF; Hoitsma AJ
Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
[TBL] [Abstract][Full Text] [Related]
28. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.
Fatfat M; Fakhoury I; Habli Z; Mismar R; Gali-Muhtasib H
Life Sci; 2019 Sep; 232():116628. PubMed ID: 31278946
[TBL] [Abstract][Full Text] [Related]
29. Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.
Hasegawa H; Bissonnette RP; Gillings M; Sasaki D; Taniguchi H; Kitanosono H; Tsuruda K; Kosai K; Uno N; Morinaga Y; Imaizumi Y; Miyazaki Y; Yanagihara K
Cancer Sci; 2016 Aug; 107(8):1124-33. PubMed ID: 27193821
[TBL] [Abstract][Full Text] [Related]
30. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Waldmann TA
Oncogene; 2007 May; 26(25):3699-703. PubMed ID: 17530023
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
Zhang M; Yao Z; Garmestani K; Yu S; Goldman CK; Paik CH; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2009 Jun; 24(3):303-9. PubMed ID: 19538052
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
33. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Rech AJ; Vonderheide RH
Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
[TBL] [Abstract][Full Text] [Related]
34. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model.
Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
[TBL] [Abstract][Full Text] [Related]
35. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
Zhang M; Yao Z; Garmestani K; Axworthy DB; Zhang Z; Mallett RW; Theodore LJ; Goldman CK; Brechbiel MW; Carrasquillo JA; Waldmann TA
Blood; 2002 Jul; 100(1):208-16. PubMed ID: 12070029
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Mori N; Matsuda T; Tadano M; Kinjo T; Yamada Y; Tsukasaki K; Ikeda S; Yamasaki Y; Tanaka Y; Ohta T; Iwamasa T; Tomonaga M; Yamamoto N
J Virol; 2004 May; 78(9):4582-90. PubMed ID: 15078940
[TBL] [Abstract][Full Text] [Related]
37. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells.
Monti P; Brigatti C; Heninger AK; Scirpoli M; Bonifacio E
Am J Transplant; 2009 Dec; 9(12):2727-35. PubMed ID: 19788505
[TBL] [Abstract][Full Text] [Related]
38. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
Przepiorka D; Kernan NA; Ippoliti C; Papadopoulos EB; Giralt S; Khouri I; Lu JG; Gajewski J; Durett A; Cleary K; Champlin R; Andersson BS; Light S
Blood; 2000 Jan; 95(1):83-9. PubMed ID: 10607689
[TBL] [Abstract][Full Text] [Related]
39. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.
Olin RL; Nichols KE; Naghashpour M; Wasik M; Shelly B; Stadtmauer EA; Vogl DT
Am J Hematol; 2008 Sep; 83(9):747-9. PubMed ID: 18615554
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Pise-Masison CA; Radonovich M; Dohoney K; Morris JC; O'Mahony D; Lee MJ; Trepel J; Waldmann TA; Janik JE; Brady JN
Blood; 2009 Apr; 113(17):4016-26. PubMed ID: 19131553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
